Adverse event comparison between glucagon‐like peptide‐1 receptor agonists and other antiobesity medications following bariatric surgery

Ähnliche Einträge

• Real‐world titration, persistence & weight loss of semaglutide and tirzepatide in an academic obesity clinic
  von: Jason M. Samuels, et al.
  Veröffentlicht: (2025)
• Risks of peri‐ and postoperative complications with glucagon‐like peptide‐1 receptor agonists
  von: David C. Klonoff, et al.
  Veröffentlicht: (2024)
• Suicidality among users of glucagon‐like peptide‐1 receptor agonists: An emerging signal?
  von: Darren Lau, et al.
  Veröffentlicht: (2024)
• A long‐acting glucose‐dependent insulinotropic polypeptide receptor agonist improves the gastrointestinal tolerability of glucagon‐like peptide‐1 receptor agonist therapy
  von: Filip K. Knop, et al.
  Veröffentlicht: (2024)
• Real‐world use of glucagon‐like peptide‐1 receptor agonists in youth with type 2 diabetes is associated with short‐term improvements in HbA1c
  von: Stephanie L. Samuels, et al.
  Veröffentlicht: (2024)